Cancer Drug Access and Innovation Under the Inflation Reduction Act-A Balancing Act

Stacie B Dusetzina; Frank S David

doi:10.1001/jamaoncol.2024.4745

Cancer Drug Access and Innovation Under the Inflation Reduction Act-A Balancing Act

JAMA Oncol. 2024 Dec 1;10(12):1614-1615. doi: 10.1001/jamaoncol.2024.4745.

Authors

Stacie B Dusetzina^{1

2}, Frank S David^{3

4}

Affiliations

¹ Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
² Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
³ Pharmagellan LLC, Milton, Massachusetts.
⁴ Department of Biology, Tufts University, Medford, Massachusetts.

PMID: 39446358
DOI: 10.1001/jamaoncol.2024.4745

No abstract available

Plain language summary

This Viewpoint explores whether the Inflation Reduction Act’s provisions and price negotiations could affect investment in trials of new oncology therapies or indications.